Evidence mapPaperPMID 41876459Full record

ArticleCancer biology & therapy2026

Epigenetic silencing

Yuan Li, Aiai Gao, Yuanxin Yao, Meiying Zhang, Lianlian Jin, Qian Tao, Mingzhou Guo

Abstract read
In one paragraph

Article in Cancer biology & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yuan LiHenan Institute of Advanced Technology, Zhengzhou University, Zhengzhou, Henan, China.
Aiai GaoDepartment of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.
Yuanxin YaoDepartment of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.
Meiying ZhangDepartment of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.
Lianlian JinDepartment of Gastroenterology and Hepatology, The Third Affiliated Hospital of Xinxiang Medical University, Xinxiang, Henan, China.
Qian TaoCancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Translational Oncology, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
Mingzhou GuoDepartment of Gastroenterology and Hepatology, Chinese PLA General Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEsophageal squamous cell carcinoma (ESCC) remains a deadly disease, with no effective therapeutics available for advanced stages. The application of the "synthetic lethality" principle to cancers with abnormal epigenetic changes provides more opportunities for developing novel therapeutic strategies. It is necessary to identify more molecules that are involved in the DNA damage repair response or cell fate determination to reach this end. Malignant brain tumor (MBT) domain proteins are important for development and cell fate.

methodsLentiviral infection was used to re-express

resultsThe expression of

conclusion

Indexed as

DNA-Activated Protein KinaseEpigenesis, GeneticEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaNuclear ProteinsAnimalsApoptosisCell Line, TumorCell ProliferationDNA MethylationGene Expression Regulation, NeoplasticGene SilencingHumansMiceXenograft Model Antitumor AssaysDNA-Activated Protein KinaseNuclear ProteinsPRKDC protein, humanDNA methylationESCCL3MBTL4NU7441synthetic lethality

Identifiers

PMID41876459
PMCPMC13020868

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.